4/A: Amicus Therapeutics Executive Chairman John Crowley Corrects Previous SEC Filing, Reports Stock Transactions

John Crowley, Executive Chairman of Amicus Therapeutics, files an amended SEC Form 4 to correct previously reported transactions involving common stock, including acquisitions and disposals.

Summary

• John Crowley, the Executive Chairman of Amicus Therapeutics, filed an amended Form 4 with the SEC to correct errors in a previous filing from January 11, 2024.
• The amendment addresses the acquisition of 57,620 shares granted for achieving the 2021 Performance-Based Restricted Stock Unit (PRSU) Total Shareholder Return (TSR) goal.
• The original filing inadvertently excluded these shares and reported incorrect holdings after shares were withheld for taxes and a sale transaction occurred.
• The corrected filing shows that on January 9, 2024, Crowley acquired 57,620 shares at $0.00 due to the PRSU TSR goal achievement.
• Also on January 9, 2024, 36,865 shares were disposed of at $13.65 per share to cover tax obligations.
• On January 10, 2024, Crowley sold 31,614 shares at a weighted average price of $13.6475 per share.
• Following these transactions, Crowley beneficially owns 927,013 shares of Amicus Therapeutics common stock.
• The sale transaction was executed under a Rule 10b5-1 trading plan adopted on September 6, 2023.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The correction of the filing ensures transparency, and the acquisition of shares due to performance goals is a positive sign. However, the sale of shares for tax purposes and under a pre-arranged plan is a routine event.

Positives

• The filing corrects a previous error, providing accurate information to investors.
• The acquisition of shares reflects the achievement of performance goals, which can be seen as a positive indicator.

Industry Context

This filing is a routine disclosure related to insider trading activities, which are common for executives of publicly traded companies. The use of a 10b5-1 trading plan is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• Executive stock transactions are a normal part of compensation and wealth management in publicly traded companies.
• The use of Rule 10b5-1 trading plans is a common practice among executives to schedule stock sales and avoid insider trading concerns, similar to practices at companies like Regeneron or Vertex Pharmaceuticals.
• The reporting requirements and transparency are consistent with SEC regulations and industry standards.

Stakeholder Impact

• Shareholders benefit from accurate and transparent reporting of insider transactions.
• The transactions themselves may have a minor impact on the stock price due to the volume of shares involved.

Key Dates